NLS Pharmaceutics Closes Private Placement
Ticker: NCEL · Form: 6-K · Filed: Oct 11, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 11, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $3, $3.2 million, $4.25, $4.0 million, $4.96 |
| Sentiment | neutral |
Sentiment: neutral
Topics: private-placement, financing, shares, warrants
TL;DR
NLS Pharmaceutics just sold shares & warrants in a private placement on Oct 9th.
AI Summary
On October 9, 2024, NLS Pharmaceutics Ltd. entered into an Equity Purchase Agreement with accredited investors for a private placement. The company agreed to issue and sell 806,452 common shares, with a par value of CHF 0.80 per share, and common share purchase warrants.
Why It Matters
This private placement provides NLS Pharmaceutics with capital through the issuance of shares and warrants, potentially funding its ongoing operations and development.
Risk Assessment
Risk Level: medium — Private placements can dilute existing shareholders and the success of the company depends on the use of these funds.
Key Numbers
- 806,452 — Common Shares (Issued in private placement on October 9, 2024)
- CHF 0.80 — Par Value (Per common share)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- October 9, 2024 (date) — Date of Equity Purchase Agreement
- 806,452 (number) — Number of common shares issued
- CHF 0.80 (dollar_amount) — Par value per common share
FAQ
What is the total number of common shares NLS Pharmaceutics agreed to issue in the private placement?
NLS Pharmaceutics agreed to issue 806,452 common shares.
On what date did NLS Pharmaceutics enter into the Equity Purchase Agreement?
The company entered into the Equity Purchase Agreement on October 9, 2024.
What is the par value of each common share being issued?
The par value of each common share is CHF 0.80.
Who are the parties involved in the Equity Purchase Agreement?
NLS Pharmaceutics Ltd. and certain accredited investors are the parties involved.
What other securities, besides common shares, did NLS Pharmaceutics agree to issue?
NLS Pharmaceutics also agreed to issue common share purchase warrants.
Filing Stats: 1,286 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2024-10-11 07:00:11
Key Financial Figures
- $3 — Shares, at a combined purchase price of $3.97, for aggregate gross proceeds of $3.
- $3.2 million — $3.97, for aggregate gross proceeds of $3.2 million. The Common Warrants have a term of fiv
- $4.25 — ive years and have an exercise price of $4.25 per share. Pursuant to the Equity Purch
- $4.0 million — rsquo;s debt in the aggregate amount of $4.0 million held by the investor, the Company agree
- $4.96 — referred shares, at a purchase price of $4.96 (rounded). The preferred shares contain
- $10.0 million — e right to purchase up to an additional $10.0 million worth of convertible preferred shares b
Filing Documents
- ea0217306-6k_nlspharm.htm (6-K) — 24KB
- ea021730601ex99-1_nlspharm.htm (EX-99.1) — 85KB
- ea021730601ex99-2_nlspharm.htm (EX-99.2) — 388KB
- ea021730601ex99-3_nlspharm.htm (EX-99.3) — 443KB
- ea021730601ex99-4_nlspharm.htm (EX-99.4) — 32KB
- ea021730601ex99-5_nlspharm.htm (EX-99.5) — 80KB
- ea021730601ex99-6_nlspharm.htm (EX-99.6) — 154KB
- ea021730601ex99-7_nlspharm.htm (EX-99.7) — 193KB
- ea021730601ex99-8_nlspharm.htm (EX-99.8) — 365KB
- 0001213900-24-087049.txt ( ) — 1767KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 11, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 4